<p>根据 MPM Bioimpact LLC 最近向证券交易委员会（SEC）披露的信息，该公司在第四季度购买了 Vera Therapeutics, Inc.（NASDAQ:VERA - 免费报告）的新头寸。该基金购买了 257,788 股公司股票，价值约为 10,902,000 美元。截至其最近的 SEC 备案，MPM Bioimpact LLC 持有 Vera Therapeutics 的 0.41%。</p>
<p>获取 <strong>Vera Therapeutics</strong> 警报：</p>
<p>其他大型投资者最近也对该公司的头寸进行了调整。Avoro Capital Advisors LLC 在第四季度将其在 Vera Therapeutics 的股份提高了 30.2%。Avoro Capital Advisors LLC 现在拥有 5,610,000 股公司股票，价值 237,247,000 美元，在上个季度又购买了 1,300,410 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Vera Therapeutics 的股份提高了 11.1%。Price T Rowe Associates Inc. MD 现在拥有 4,377,049 股公司股票，价值 185,107,000 美元，在上个季度又收购了 437,940 股。FMR LLC 在第四季度将其在 Vera Therapeutics 的头寸提高了 9.6%。FMR LLC 现在拥有 3,053,126 股公司股票，价值 129,117,000 美元，在上个季度又购买了 267,842 股。Vanguard Group Inc.在第四季度将其在 Vera Therapeutics 的股份提高了 14.3%。Vanguard Group Inc.现在拥有 2,949,564 股公司股票，价值 124,737,000 美元，在此期间又购买了 369,387 股。最后，Paradigm Biocapital Advisors LP 在第四季度将其在 Vera Therapeutics 的持股提高了 31.0%。Paradigm Biocapital Advisors LP 现在拥有 1,437,339 股公司股票，价值 60,785,000 美元，在上个季度又收购了 340,488 股。目前 99.21% 的股票由机构投资者持有。</p>
<h2>Vera Therapeutics 股票表现</h2>
<p>VERA 股票周三开盘价为 21.58 美元。该公司的市值为 13.8 亿美元，市盈率为-8.27，贝塔值为 1.28。公司的债务与股本比率为 0.17，流动比率为 13.76，速动比率为 13.76。Vera Therapeutics, Inc.的 12 个月低点为 18.53 美元，12 个月高点为 51.61 美元。公司的 50 日移动平均价格为 23.92 美元，200 日移动平均价格为 34.43 美元。</p>
<p>Vera Therapeutics（NASDAQ:VERA - 获取免费报告）最后一次公布季度财报是在 5 月 8 日星期四。该公司报告每股收益（EPS）为-0.81 美元，低于分析师一致预期的-0.75 美元，差距为 0.06 美元。在去年同期，该公司每股收益为-0.56 美元。研究分析师预计 Vera Therapeutics, Inc.在当前财政年度将发布-2.89 的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>VERA 已成为多份研究分析师报告的主题。摩根大通将 Vera Therapeutics 的股票目标价从 77.00 美元下调至 71.00 美元，并在 3 月 4 日的报告中给予该股票 “增持” 评级。Guggenheim 将 Vera Therapeutics 的股票目标价从 59.00 美元上调至 61.00 美元，并在 2 月 27 日的研究报告中给予该股票 “买入” 评级。Wolfe Research 在 2 月 4 日的研究报告中开始覆盖 Vera Therapeutics 的股票。他们给予该股票 “跑赢大盘” 评级，目标价为 49.00 美元。HC Wainwright 在 5 月 5 日的研究报告中开始覆盖 Vera Therapeutics 的股票。他们给予该股票 “买入” 评级，目标价为 75.00 美元。最后，高盛集团在 1 月 28 日的研究报告中开始覆盖 Vera Therapeutics 的股票。他们给予该股票 “买入” 评级，目标价为 58.00 美元。一位投资分析师对该股票给予持有评级，七位给予买入评级，两位给予强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，共识目标价为 63.33 美元。</p>
<p><strong>查看我们关于 Vera Therapeutics 的最新股票报告</strong></p>
<h2>关于 Vera Therapeutics</h2>
<p>（免费报告）</p>
<p>Vera Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的治疗。其主要产品候选药物为 atacicept，这是一种以皮下注射方式自我给药的融合蛋白，目前正在进行针对免疫球蛋白 A 肾病患者的第三阶段临床试验；以及针对狼疮性肾炎的治疗，目前正在进行第二阶段临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
<li>股票评级和建议：理解分析师评级</li>
<li>制药行业抛售：RSI 表示你不应忽视的三只股票</li>
<li>如何投资生物技术股票</li>
<li>AppLovin 因财报大涨：这家科技公司接下来会怎样？</li>
<li>股息支付比率计算器</li>
<li>美国监管机构针对 CrowdStrike：这是信号还是噪音？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vera Therapeutics 吗？</h2>
<p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中被评为买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

VERA

<p>MPM Bioimpact LLC 在 Vera Therapeutics, Inc.（纳斯达克代码：VERA）中获得了新头寸，在第四季度购买了 257,788 股，价值约为 1090 万美元。其他机构投资者，包括 Avoro Capital Advisors 和 Price T Rowe Associates，也增加了对该公司的持股。Vera Therapeutics 的市值为 13.8 亿美元，报告的季度每股收益为（$0.81），未达到预期。分析师对该股票的共识评级为 “买入”，平均目标价为 63.33 美元</p>

<p>MPM Bioimpact LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 257,788 shares of the company's stock, valued at approximately $10,902,000. MPM Bioimpact LLC owned 0.41% of Vera Therapeutics as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 MPM Bioimpact LLC 最近向证券交易委员会（SEC）披露的信息，该公司在第四季度购买了 Vera Therapeutics, Inc.（NASDAQ:VERA - 免费报告）的新头寸。该基金购买了 257,788 股公司股票，价值约为 10,902,000 美元。截至其最近的 SEC 备案，MPM Bioimpact LLC 持有 Vera Therapeutics 的 0.41%。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 警报：</p>
</div><p>Other large investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after buying an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock valued at $185,107,000 after acquiring an additional 437,940 shares during the last quarter. FMR LLC lifted its position in Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after buying an additional 267,842 shares during the last quarter. Vanguard Group Inc. increased its stake in Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after purchasing an additional 369,387 shares during the period. Finally, Paradigm Biocapital Advisors LP raised its holdings in shares of Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after acquiring an additional 340,488 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的头寸进行了调整。Avoro Capital Advisors LLC 在第四季度将其在 Vera Therapeutics 的股份提高了 30.2%。Avoro Capital Advisors LLC 现在拥有 5,610,000 股公司股票，价值 237,247,000 美元，在上个季度又购买了 1,300,410 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Vera Therapeutics 的股份提高了 11.1%。Price T Rowe Associates Inc. MD 现在拥有 4,377,049 股公司股票，价值 185,107,000 美元，在上个季度又收购了 437,940 股。FMR LLC 在第四季度将其在 Vera Therapeutics 的头寸提高了 9.6%。FMR LLC 现在拥有 3,053,126 股公司股票，价值 129,117,000 美元，在上个季度又购买了 267,842 股。Vanguard Group Inc.在第四季度将其在 Vera Therapeutics 的股份提高了 14.3%。Vanguard Group Inc.现在拥有 2,949,564 股公司股票，价值 124,737,000 美元，在此期间又购买了 369,387 股。最后，Paradigm Biocapital Advisors LP 在第四季度将其在 Vera Therapeutics 的持股提高了 31.0%。Paradigm Biocapital Advisors LP 现在拥有 1,437,339 股公司股票，价值 60,785,000 美元，在上个季度又收购了 340,488 股。目前 99.21% 的股票由机构投资者持有。</p>
</div><h2>Vera Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票表现</h2>
</div><p>Shares of VERA stock opened at $21.58 on Wednesday. The firm has a market capitalization of $1.38 billion, a P/E ratio of -8.27 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company's fifty day moving average price is $23.92 and its two-hundred day moving average price is $34.43.</p>
<div class="lb-trans"><p>VERA 股票周三开盘价为 21.58 美元。该公司的市值为 13.8 亿美元，市盈率为-8.27，贝塔值为 1.28。公司的债务与股本比率为 0.17，流动比率为 13.76，速动比率为 13.76。Vera Therapeutics, Inc.的 12 个月低点为 18.53 美元，12 个月高点为 51.61 美元。公司的 50 日移动平均价格为 23.92 美元，200 日移动平均价格为 34.43 美元。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the business posted ($0.56) earnings per share. On average, research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vera Therapeutics（NASDAQ:VERA - 获取免费报告）最后一次公布季度财报是在 5 月 8 日星期四。该公司报告每股收益（EPS）为-0.81 美元，低于分析师一致预期的-0.75 美元，差距为 0.06 美元。在去年同期，该公司每股收益为-0.56 美元。研究分析师预计 Vera Therapeutics, Inc.在当前财政年度将发布-2.89 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>VERA has been the topic of a number of research analyst reports. JPMorgan Chase &amp; Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, March 4th. Guggenheim upped their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 27th. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an &#34;outperform&#34; rating and a $49.00 price target on the stock. HC Wainwright started coverage on shares of Vera Therapeutics in a research report on Monday, May 5th. They set a &#34;buy&#34; rating and a $75.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They issued a &#34;buy&#34; rating and a $58.00 target price on the stock. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $63.33.</p>
<div class="lb-trans"><p>VERA 已成为多份研究分析师报告的主题。摩根大通将 Vera Therapeutics 的股票目标价从 77.00 美元下调至 71.00 美元，并在 3 月 4 日的报告中给予该股票 “增持” 评级。Guggenheim 将 Vera Therapeutics 的股票目标价从 59.00 美元上调至 61.00 美元，并在 2 月 27 日的研究报告中给予该股票 “买入” 评级。Wolfe Research 在 2 月 4 日的研究报告中开始覆盖 Vera Therapeutics 的股票。他们给予该股票 “跑赢大盘” 评级，目标价为 49.00 美元。HC Wainwright 在 5 月 5 日的研究报告中开始覆盖 Vera Therapeutics 的股票。他们给予该股票 “买入” 评级，目标价为 75.00 美元。最后，高盛集团在 1 月 28 日的研究报告中开始覆盖 Vera Therapeutics 的股票。他们给予该股票 “买入” 评级，目标价为 58.00 美元。一位投资分析师对该股票给予持有评级，七位给予买入评级，两位给予强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，共识目标价为 63.33 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Vera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Vera Therapeutics 的最新股票报告</strong></p>
</div><h2>About Vera Therapeutics</h2>
<div class="lb-trans"><h2>关于 Vera Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的治疗。其主要产品候选药物为 atacicept，这是一种以皮下注射方式自我给药的融合蛋白，目前正在进行针对免疫球蛋白 A 肾病患者的第三阶段临床试验；以及针对狼疮性肾炎的治疗，目前正在进行第二阶段临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
<li>How to Invest in Biotech Stocks</li>
<li>AppLovin Surges on Earnings: What's Next for This Tech Standout?</li>
<li>Dividend Payout Ratio Calculator</li>
<li>U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Vera Therapeutics</li>
<li>股票评级和建议：理解分析师评级</li>
<li>制药行业抛售：RSI 表示你不应忽视的三只股票</li>
<li>如何投资生物技术股票</li>
<li>AppLovin 因财报大涨：这家科技公司接下来会怎样？</li>
<li>股息支付比率计算器</li>
<li>美国监管机构针对 CrowdStrike：这是信号还是噪音？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中被评为买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

MPM Bioimpact LLC 在 Vera Therapeutics, Inc. (NASDAQ:VERA) 中收购了新的持仓